Why does the franchise agreement charge no upfront franchise fee when the typical range for this category is $39,500-$54,625, and how does this affect your cost structure and franchisee commitment levels?
#1
Can you explain the significant discrepancy between your 3.0% royalty rate and the typical 6.0-7.0% range for pharmacy franchises, and whether this lower rate is sustainable long-term?
#2
What specific disputes led to the 5 litigation cases filed in the past 3 years, and can you provide details on the 2 pending cases and their anticipated outcomes?
#3
Of the 4 cases where the franchisor was a defendant, what were the primary allegations and have any resulted in judgments or settlements against the company?
#4
Regarding the 4 cases initiated by the franchisor as plaintiff, what percentage involved franchisee disputes versus other parties like suppliers or employees?
#5
The system lost 13 units over 3 years (from 67 to 59). What are the primary reasons for closures and terminations, and are there specific market or operational issues driving these exits?
#6
In 2023, there were 7 closures and 7 terminations from a base of 67 units. Were these terminations franchisor-initiated or franchisee non-renewals, and what triggered them?
#7
Given the 0% transfer rate in 2025, why are existing franchisees not transferring their units to new operators, and does this reflect limited secondary market demand?
#8
Why does the initial franchise term last only 5 years when the typical range is 10 years, and what happens at the end of the 5-year term if a franchisee wishes to continue?
#9
The franchise agreement specifies only 1 renewal condition versus the typical 6-9. What specific conditions must be met for renewal, and are renewal terms automatically granted?
#10
You offer zero miles and zero years of non-compete protection. How does this affect franchisee location security, and can another franchisee open next to an existing unit after termination?
#11
The $1,000 transfer fee is substantially below the typical $7,500-$20,000 range. Does this low fee apply to voluntary transfers, franchisor-approved transfers, or both?
#12
Can you clarify the binding arbitration and venue provisions that limit disputes to Franklin County, Ohio? How does this affect franchisees located outside Ohio who wish to dispute franchisor actions?
#13
The franchise agreement requires personal guarantees from all owners. If a franchisee defaults, what specific provisions of the agreement trigger the guarantee, and have you enforced personal guarantees in past litigation?
#14
Item 19 financial performance data is not included in your FDD. Can you provide median or average gross sales figures for operating units, and how many units reported this data?
#15
What specific support and training does the franchisor provide given that no technology fee is charged beyond the $300 annual fee, and what is included in that $300?
#16
Of the 6 closures in 2024 and 4 closures in 2025, how many were voluntary (franchisee choice) versus involuntary (franchisor termination or non-renewal)?
#17
The system health score of 24/100 is significantly below the typical 50-75 range. What specific operational or compliance issues contribute to this low score?
#18
Why is there no territory exclusivity or encroachment protection when these are standard in comparable pharmacy franchise systems?
#19
Given the 2 pending litigation cases, what is the financial exposure and timeline for resolution, and could outcomes materially impact franchisees?
#20